

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/ Allogeneic	Site(s) in Sweden	Start Year
Uppsala University	A Phase I-IIa Study of Dose escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma.	NCT00891748 2006-000985-34	CD40L gene therapy. adenoviral vector	I/II	Completed	Oncology - urology	Urinary bladder cancer	GTMP	N/A	Yes, in vivo		Uppsala University Hospital, Uppsala	2006
Uppsala University	DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients With Relapsed Prostate Cancer. A Phase I/II Study.	NCT00859729 2006-001128-38	Biological: pVAXrcPSAv531 (DNA encoding rhesus PSA) Device: DERMA VAX™ intradermal DNA delivery system	I/II	Completed	Oncology - urology	Prostate cancer	GTMP	N/A	Yes, in vivo		Uppsala University Hospital, Uppsala	2008
Uppsala University	Phase I/IIa AdCD40L allogeneic dendritic-cell based therapeutic vaccine.	NCT01455259 2010-023103-94	CD40L gene therapy	I/IIa	Completed	Oncology	Malignant melanoma	GTMP	N/A	Yes, in vivo		Uppsala University Hospital, Uppsala	2011
Mendus	IM101. A Phase I Open-label study to evaluate Safety and Immunologic Response of COMBIG-DC administered Intratumorally in Patients with Metastatic Renal Cell Carcinoma.	NCT01525017 2011-002039-25	COMBIG-DC. ilixadencel. allogeneic dendritic-cell based therapeutic vaccine	I	Completed	Oncology	Metastatic Renal Cell Carcinoma (mRCC)	sCTMP	Dendritic cells	No	Allogeneic	Uppsala University Hospital, Uppsala	2012
Uppsala University	CAR 19 003. CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.	NCT02132624 2013-001393-19	CAR T cells (CD192841BBz) retroviral vector	I/IIa (FiH)	Completed	Oncology/ hematology	Refractory B Cells Malignancy	GTMP	T cells	Yes, ex vivo	Autologous	Uppsala University Hospital, Uppsala	2014
Mendus	MERCA, IM-201. An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib, post-nephrectomy, compared to Sunitinib post-nephrectomy in metastatic renal cell carcinoma patients.	NCT02432846 2014-004510-28	Intuvax (ilixadencel)	II	Completed	Oncology	Metastatic Renal Cell Carcinoma (mRCC)	sCTMP	Preactivated allogeneic dendritic cells	No	Allogeneic	Uppsala University Hospital, Uppsala	2015
BioNTech	MERIT. First-in-human clinical study with RNA-Immunotherapy combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumour Therapy in Triple negative Breast Cancer Patients.	NCT02316457 2014-002274-37	IVAC MUTANOME® RNA	I	Completed	Oncology	Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast Cancer (Triple Negative Breast Cancer (TNBC))	GTMP	N/A			Uppsala University Hospital, Uppsala	2016
Uppsala University	RADNET. Study of Recombinant Adenovirus Advince in Patients With Neuroendocrine Tumors; Safety and Efficacy.	NCT02749331 2014-000614-64	Advince Ad5PTD(CgA-E1AmiR122) oncolytic adenovirus	I/IIa (FiH)	Recruiting	Oncology	Progressive neuroendocrine neoplasms with liver metastasis	GTMP	N/A	Yes, in vivo		Uppsala University Hospital, Uppsala	2016
Uppsala University	CAR 19 004. CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy.	NCT03068416 2016-004043-36	CAR T cells (CD192841BBz). retroviral vector	II	Completed	Oncology/ hematology	Refractory B Cells Malignancy	GTMP	T cells	Yes, ex vivo	Autologous	Uppsala University Hospital, Uppsala	2017

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/Allogeneic	Site(s) in Sweden	Start Year
NextCell Pharma Ab	PROTRANS 1. Wharton's Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes.	NCT03406585 2017-002766-50	Mesenchymal stromal cells	I/II	Completed	Endocrinology	Type 1 Diabetes Mellitus	TEP	Mesenchymal stromal cells	No	Allogeneic	Uppsala University Hospital, Uppsala	2017
Kite/Gilead	ZUMA-7. A Phase 3, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma.	NCT03391466 2017-002261-22	axicabtagene ciloleucel (Yescarta)  retroviral vector: (MSCV)-based splice-gag $\gamma$ -retroviral vector (MSGV1).	III	In follow-up	Oncology	Diffuse large B cell lymphoma (DLBCL)	GTMP	T cells	Yes, ex vivo	Autologous	Skåne University Hospital, Lund Uppsala University Hospital, Uppsala	2018
Celgene	TRANSFORM, CA082-1170. A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas.	NCT03575351 2018-000929-32	Lisocabtagene Maraleucel	III	In planning/ set-up	Oncology	Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas	GTMP	T cells	Yes, ex vivo	Autologous	Karolinska University Hospital, Stockholm	2018
CSL Behring/ UniQure	AMT-061. Phase III, open-label, single-dose, multi-centre multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately-severe hemophilia B.	NCT03569891 2017-004305-40	Etranacogene dezaparovec. AAV5 (Factor IX).	III	In follow-up	Haematology	Hemophilia B	GTMP	N/A	Yes, in vivo		Skåne University Hospital, Malmö	2019
LOKON Pharma	LOKON002. Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer.	2017-002565-22	delolimogene mupadenorepvec (LOAd703).  oncolytic adenovirus	I/II	Completed	Oncology - endocrinology	Pancreatic and ovarian cancer	GTMP	N/A	Yes, in vivo		Karolinska University Hospital, Stockholm Uppsala University Hospital, Uppsala	2019
NextCell Pharma Ab	PROTRANS 2. Wharton's Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes.	NCT03973827 2018-004158-11	Protrans Mesenchymal stromal cells	I/II	In follow-up	Endocrinology	Type 1 Diabetes Mellitus	TEP	Mesenchymal stromal cells	No	Allogeneic	Uppsala University Hospital, Uppsala	2019
NextCell Pharma AB	Treatment of Respiratory Complications Associated With COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus Infection Using Wharton's Jelly-Umbilical Cord Mesenchymal Stromal Cells (ProTrans®): Open Phase IB Clinical Trial.	NCT04896853 2020-002078-29	ProTrans®	Ib	Recruiting	COVID-19 Acute Respiratory Distress Syndrome	Severe respiratory complications associated with pneumonia caused by COVID-19.	TEP	Wharton's Jelly-Umbilical Cord Mesenchymal Stromal Cells	No	Allogeneic	Örebro University Hospital, Örebro	2020
Uppsala University Hospital	ARDS-MSC-205 (Covid19). Mesenchymal stromal cell therapy for the treatment of acute respiratory distress syndrome. Validation of Mechanistic Pathways and Clinical Efficacy.	NCT04447833 2019-004462-18	allogeneic BM-MSC: EMA/864885/2016	I	In follow-up	Acute Respiratory Distress Syndrome, Adult	COVID19-induced ARDS	sCTMP	Mesenchymal stromal cells	No	Allogeneic	Uppsala University Hospital, Uppsala	2020

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/Allogeneic	Site(s) in Sweden	Start Year
LOKON Pharma	LOKON003. A Phase I/II Trial Investigating LOAd703 in Combination with Atezolizumab in Malignant Melanoma.	NCT04123470 2019-003300-12	delolimogene mupadenorepvec (LOAd703).	I/II	Completed	Oncology	malignant melanoma	GTMP	N/A	Yes, in vivo		Uppsala University Hospital, Uppsala	2020
DCprime bv	Advance II. An international multicentre open-label study to evaluate the efficacy and safety of two different vaccination regimens of immunotherapy with allogeneic dendritic cells, DCP-001, in patients with acute myeloid leukemia that are in remission with persistent MRD.	NCT03697707 2017-003426-32	oncolytic adenovirus DCP-001 (DCOne). Allogeneic dendritic cell vaccine	II	Completed	Hematology	AML	sCTMP	Dendritic cells	No	Allogeneic	Uppsala University Hospital, Uppsala	2020
Region Uppsala	DSC-BROMS-1. A multicenter, open-label, randomized, phase I/II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation treated with decidual stromal cells (DSC) or best available therapy (BAT).	NCT04118556 2019-002186-36	Placenta-derived (decidua) stromal cells	I/II	Recruiting	GvHD	steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation	sCTMP	Decidua stromal cells	No	Allogeneic	Skåne University Hospital, Lund Uppsala University Hospital, Uppsala	2021
Janssen-Cilag	CARTITUDE-4. A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma.	NCT04181827 2019-001413-16	Ciltacabtagene Autoleucl (cilta-cel)  lentiviral vector	III	In follow-up	Oncology	multiple myeloma	GTMP	T cells	Yes, ex vivo	Autologous	Karolinska University Hospital, Stockholm Skåne University Hospital, Lund Uppsala University Hospital, Uppsala	2021
Novartis	Cassiopeia. A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.	NCT03876769	CTL019, Kymriah	II	Recruiting	Paediatric oncology	Paediatric and young adult patients with B-cell acute lymphoblastic leukemia (B ALL)	GTMP	T cells	Yes, ex vivo	Autologous	Karolinska University Hospital, Stockholm Sahlgrenska University Hospital, Göteborg	2021
Intellia Therapeutics	Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE).	NCT04601051	NTLA-2002  CRISPR/Cas9	I/II	In follow-up	Congenital, Hereditary, and Neonatal Diseases and Abnormalities	Hereditary Angioedema	GTMP	N/A	Yes, in vivo		University Hospital of Umeå, Umeå	2021
Pfizer/Sparks	Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C <=2%) (BeneGene-2)	NCT03861273 2022-502844-11-00	fidanacogene elaparvovec	III	In follow-up	Haematology	Hemophilia B	GTMP	N/A	Yes, in vivo		Skåne University Hospital, Malmö	2021

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/Allogeneic	Site(s) in Sweden	Start Year
AlloVir	VIR303. Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleuceel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation.	NCT05179057 2021-003450-22	Posoleuceel	III	Completed	Paediatrics - adenovirus infection after allogeneic transplantation	Adenovirus Infection after allogeneic transplantation	sCTMP	Multi-virus specific T cell therapy; Virus infected previously in hematopoietic cell transplanted patients	No	Allogeneic	Karolinska University Hospital, Stockholm Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2022

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/ Allogeneic	Site(s) in Sweden	Start Year
Ilya Pharma	SITU-HEAL (IP-CT-003). A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers.	NCT05608187 2021-000563-69	ILP100, emilimogene sigulactibac.  CXCL12- $\alpha$ via Limosilactobacillus reuteri bacteria.	Ila	Recruiting	Endocrinology, Chronic wounds.	Diabetic Foot Ulcers	GTMP	Lyophilized Lactobacillus reuteri expressing CXCL12	Yes, in vivo		Skåne University Hospital, Lund Uppsala University Hospital, Uppsala	2022
Janssen-Cilag	CARTITUDE-5. A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucl, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.	NCT04923893 2021-001242-35	Ciltacabtagene Autoleucl (cilta-cel)  lentiviral vector	III	Recruiting	Oncology	multiple myeloma	GTMP	T cells	Yes, ex vivo	Autologous	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2022
Amniotics	Amnio-PUL. A First-In-Human Phase 1b, Open-Label Trial to Evaluate Safety and Tolerability of a Novel Somatic Cell Therapy - AmnioPul-02 - in Subjects with Confirmed COVID-19.	NCT05348772 2020-004171-40	AmnioPul-02	Ib	Completed	Infectious diseases	hospitalized moderate to severe SARS-CoV-2 infection (Covid-19)	sCTMP	Allogeneic mesenchymal stem cells (MSCs) extracted from term amniotic fluid	No	Allogeneic	Skåne University Hospital, Lund	2022
Sarepta therapeutics	ENVISION. A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy.	2020-002372-13	SRP-9001/ Delandistrogene moxeparvovec	III	In planning/ set-up	Pediatrics - Neuromuscular Duchenne muscular Dystrophy	Duchenne muscular Dystrophy	GTMP		Yes, in vivo		Sahlgrenska University Hospital, Göteborg Karolinska University Hospital, Stockholm	2022
Miltenyi	Miltenyi DALY 2-EU. A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/ refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.	2020-003908-14	MB-CART2019.1	II	Recruiting	Oncology/ hematology	Relapsed/ refractory diffuse large B cell lymphoma (R-R DLBCL)	GTMP	Autologous CD20-CD19 CAR transduced CD4/CD8 enriched T cells	Yes, ex vivo	Autologous	Uppsala University Hospital, Uppsala	2022
Uppsala University Hospital	PROTRANS YOUNG. A Double-blinded, Randomized, Parallel, Placebo-controlled trial of Wharton's Jelly-derived Allogeneic Mesenchymal Stromal Cells to treat Type I Diabetes in Children and Adolescents.	2020-004520-42	Mesenchymal stromal cells	I/II	Recruiting	Endocrinology	Type 1 Diabetes Mellitus	TEP	Mesenchymal stromal cells		Allogeneic	Uppsala University Hospital, Uppsala	2022

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/ Allogeneic	Site(s) in Sweden	Start Year
AnGes MG	AG-CLI-0206. A phase 3 double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of AMG0001 in subjects with critical limb ischemia.	NCT02144610 2014-001129-34	AMG0001, beperminogen perplasmid, Collategene.  Vector: Hepatocyte Growth Factor (HGF) cDNA Plasmid.	III	In follow-up	Surgery/ Cardiovascular Diseases	Critical limb ischemia	GTMP	N/A			Uppsala University Hospital, Uppsala	2022
Pfizer	Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants With Moderately Severe to Severe Hemophilia A(FVIII:C≤1%)	NCT04370054 2019-004451-37	giroctogene fitelparvec	III	In follow-up	Haematology	Hemophilia A	GTMP	N/A	Yes, in vivo		Skåne University Hospital, Malmö	2022
Region Skåne	STEM-PD trial: A multicentre, single arm, first in human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell derived dopaminergic cells for Parkinson's disease (STEM-PD product).	NCT05635409 2021-001366-38	STEM-PD	I/IIa (FIH)	Recruiting	Neurology	Parkinson disease	sCTMP	Human embryonic stem cell (hESC) derived dopaminergic cells	No	Allogeneic	Skåne University Hospital, Lund	2023

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/Allogeneic	Site(s) in Sweden	Start Year
BioNTech SE	BNT 122-01. A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection.	NCT04486378 2020-000451-12	RO7198457. Personalized cancer vaccine (PCV), liposomally formulated mRNA encoding up to 20 tumor neoantigens.	II	Recruiting	Oncology	Colorectal cancer stage II and III	GTMP	N/A	Yes, in vivo		Skåne University Hospital, Lund	2023
European Myeloma Network	CARTITUDE-6. A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and (DVRd) followed by Ciltacabtagene Autoleucl versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible.	NCT05257083 2021-003284-10	Ciltacabtagene Autoleucl (cilta-cel)  lentiviral vector	III	Recruiting	Oncology	multiple myeloma	GTMP	T cells	Yes, ex vivo	Autologous	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund. Uppsala University Hospital, Uppsala	2023
Xintela	XIN-XSTEM-201. A single-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin $\alpha 10\beta 1$ - selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers.	NCT05549609 2022-000492-39	XSTEM-VLU	I/II	Recruiting	Skin. Chronic wounds	Venous leg ulcers	sCTMP	Integrin $\alpha 10\beta 1$ - selected mesenchymal stem cells	No	Allogeneic	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2023
Göteborg University	HAITILS. A Phase I Study Using Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases.	NCT04812470 2020-006126-31	Autologous Tumor Infiltrating Lymphocytes	I	Recruiting	Oncology - melanoma	Patients with melanoma and liver metastases		Tumor Infiltrating Lymphocytes		Autologous	Sahlgrenska University Hospital, Göteborg	2023
Merck Sharp & Dohme LLC	A Phase 3, Randomized, Double-Blind, Placebo- and Active- Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma.	NCT05933577 2023-503652-27-00	mRNA-4157 (V940).  liposomally formulated mRNA.	III	Recruiting	Oncology	Malignant melanoma	GTMP	N/A	Yes, in vivo		Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2023
Intellia Therapeutics	Long-Term Follow-Up of Subjects Treated With NTLA-2001.	NCT05697861	NTLA-2001  CRISPR/Cas10		In follow-up	Transthyretin- Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin- Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis.		GTMP	N/A	Yes, in vivo		University Hospital of Umeå, Umeå	2023

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/Allogeneic	Site(s) in Sweden	Start Year
	CLDN 6. Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors.	2019-004323-20, NCT04503278	Cloudin-6 BNT211-01	I/IIa	In planning/ set-up	Oncology - advanced solid tumors	relapsed/ refractory CLDN6 positive tumors	GTMP	CAR T cells	Yes, ex vivo	Autologous	Karolinska University Hospital, Stockholm	2023
Syneos Health	IDUNN. A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial).	2019-001462-15	MC0518	III		aGvHD	steroid refractory aGvHD		Mesenchymal stromal cells			Karolinska University Hospital, Stockholm	2023
Iovance	Study to Investigate LifileuceL Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.	NCT05727904	TILs		In planning/ set-up	Oncology	malignant melanoma	sCTMP	Tumor Infiltrating Lymphocytes	No	Autologous	Sahlgrenska University Hospital, Göteborg	2024



Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/Allogeneic	Site(s) in Sweden	Start Year
Uppsala University	CARMA-01. A Phase I/IIa multicenter study evaluating the safety and efficacy of CAR20(NAP)-T in patients with relapsed/refractory B cell lymphoma.	NCT06002659 2022-004157-31	CAR20(NAP)	I/IIa (FiH)	Recruiting	Oncology/ hematology	relapsed/refractory B cell lymphoma	GTMP	CAR T cells	Yes, ex vivo	Autologous	Uppsala University Hospital, Uppsala	2024
Uppsala University Hospital	UP421-ET1D. First-in-human safety study of hypimmune pancreatic islet transplantation in adult subjects with type 1 diabetes.	NCT06239636 2023-507988-19-00	Genetically modified human pancreatic islets (UP421).  Lentiviral vector and CRISPR/Cas are used for the genetic modification of the cells.	I (FiH)	Recruiting	Endocrinology	Type 1 Diabetes Mellitus	GTMP	Pancreatic islet cells	Yes, ex vivo	Allogeneic	Uppsala University Hospital, Uppsala	2024